Novel therapeutics in acute myeloid leukemia

Current Hematologic Malignancy Reports

Volumn 9, Issue 2, 2014, Pages 109-117

  Sweet, Kendra ^a   Lancet, Jeffrey E ^a  

^a FOB3 Heme ^*  (United States)

Author keywords

Acute myeloid leukemia; Cytotoxic chemotherapy; Heterogeneity; Novel therapeutics; Pharmacokinetically advantageous broad cytotoxics

Indexed keywords

ANTINEOPLASTIC AGENT; CPX 315; CYTARABINE; DAUNORUBICIN; ELACYTARABINE; FLAVOPIRIDOL; GEMTUZUMAB OZOGAMICIN; LINTUZUMAB; MIDOSTAURIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SGN33A; QUIZARTINIB; SAPACITABINE; SORAFENIB; UNCLASSIFIED DRUG; VOLASERTIB; VOSAROXIN; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; HUMAN; LEUKEMIA CELL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84903604431     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0199-0     Document Type: Article

References (80)

1. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485-8.
2. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-48.
3. •• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13): 1249-59. This study showed a survival benefit with higher dose daunorubicin in younger patients
4. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-36.
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903. (Pubitemid 24299870)
6. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767-75.
7. Wheatley D, Dutcher J,Wiernik P, et al. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol. 1998;103(1):100-9.
8. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of highdose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-94. (Pubitemid 41095042)
9. Patel JP, Gönen M, Figueroa ME, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. N Engl J Med. 2012;366(12):1079-89.
10. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013;2013:313-8.
11. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86.
12. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011;16(8):1162-74.
13. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 1994;91(2): 459-63. (Pubitemid 24041421)
14. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99(11):3885-91. (Pubitemid 35332023)
15. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12): 3907-14.
16. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acutemyeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-9.
17. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-42. (Pubitemid 34925124)
18. Kiyoi H, Towatari M,Yokota S, et al. Internal tandemduplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12(9):1333-7. (Pubitemid 28442377)
19. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acutemyeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92.
20. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitorKW-2449 yields insight into the basis for clinical response. Blood. 2009;113(17):3938-46.
21. Zhang W, Konopleva M, Shi Y-x, et al. Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. J Natl Cancer Inst. 2008;100(3):184-98. (Pubitemid 351480557)
22. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008;49(12):2246-55.
23. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008;22(4):808-18. (Pubitemid 351552630)
24. Ravandi F, Cortes JE, Jones D, et al. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol. 2010;28(11):1856 -62.
25. Crump M, Hedley D, Kamel-Reid S, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma. 2010;51(2): 252-60.
26. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119(22):5133-43.
27. Macdonald DA, Assouline SE, Brandwein J, et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma. 2013;54(4):760-6.
28. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655-62.
29. Serve H, Krug U, Wagner R, et al. Sorafenib in CombinationWith Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. J Clin Oncol. 2013;31(25):3110-18.
30. Al-Kali A, Cortes J, Faderl S, et al. Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia. Clinical LymphomaMyeloma Leuk. 2011;11(4):361-6.
31. Rollig C, Muller-Tidow C, Huttmann A, et al. Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients >=60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial. ASH Annu Meet Abstr. 2012;120(21):144.
32. Yi CYA, Cortes J, Faderl S, et al. Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. ASH Annu Meet Abstr. 2012;120(21):1516.
33. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145-50. (Pubitemid 39038036)
34. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54-60. (Pubitemid 40053063)
35. Fischer T, Stone RM, DeAngelo DJ, et al. Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) andMulti-Targeted Kinase Inhibitor, in PatientsWith Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. J Clin Oncol. 2010;28(28):4339-45.
36. Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. Pharmacother: J Hum Pharmacol Drug Ther. 2013;33(12)1341-52.
37. Nazha A, Kantarjian HM, Borthakur G, et al. A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5- AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). ASH Annu Meet Abstr. 2012;120(21):3587.
38. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061-8.
39. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92.
40. • Levis MJ, Perl AE, Dombret H, et al. Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. ASH Annu Meet Abstr. 2012;120(21):673. This study showed good responses with Quizartinib which is the most potent FLT3 inhibitor
41. Martinelli G, Perl AE, Dombret H, et al. Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia. ASCO Meet Abstr. 2013;31(15-suppl):7021.
42. Perl AE, Dohner H, Rousselot PH, et al. Efficacy and safety of quizartinib (AC220) in patients age >= 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML). ASCO Meet Abstr. 2013;31(15-suppl):7023.
43. Schöffski P, Awada A, Dumez H, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer. 2012;48(2):179-86.
44. Bug G, Muller-Tidow C, Schlenk RF, et al. Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. ASH Annu Meet Abstr. 2011;118(21):1549.
45. Maertens J, Lubbert M, Fiedler W, et al. Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment. ASH Annu Meet Abstr. 2012;120(21):411.
46. Karp JE, Smith BD, Levis MJ, et al. Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia. Clin Cancer Res. 2007;13(15):4467-73. (Pubitemid 47219715)
47. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-Darabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005;11(23):8403-12. (Pubitemid 41746954)
48. • Karp JE, Blackford A, Smith BD, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010;34(7):877-82. This study showed good responses in FLT3 mutated patients with FLAM
49. Zeidner JF, Gerber JM, Blackford A, et al. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH AnnuMeet Abstr. 2012;120(21): 47.
50. Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25(12):1808-14.
51. Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010;5(4):e10186.
52. Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-inclass anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66(5):881-8.
53. Roboz GJ, Lancet JE, Cripe LD, et al. Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. ASCO Meet Abstr. 2010;28(15-suppl):6526.
54. Stuart RK, Ravandi Kashani F, Cripe LD, et al. Voreloxin singleagent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. ASCO Meet Abstr. 2010;28(15-suppl):6525.
55. Lancet JE, Roboz GJ, Cripe LD, et al. Phase 1b/2 Pharmacokinetic/ Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients. ASH Annu Meet Abstr. 2009;114(22):635.
56. Freeman C,KeaneN, Swords R,Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother. 2013;14(10):1417-27.
57. Giles FJ, Vey N, Rizzieri D, et al. Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia. 2012;26(7):1686-9.
58. Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk Res. 2012;36(4):e71-3.
59. O'Brien S, Rizzieri DA, Vey N, et al. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012;158(5):581-8.
60. Dinardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP- 4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013;9(8):1073-82.
61. Adams DJ, SandvoldML,Myhren F, Jacobsen TF, Giles F, Rizzieri DA. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma. 2008;49(4):786-97. (Pubitemid 351517226)
62. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol. 2004;67(3):503-11. (Pubitemid 38232890)
63. Rizzieri DA, Vey N, Thomas X, et al. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/ Anthracycline. ASH Annu Meet Abstr. 2012;120(21):46.
64. Russell NH. Improving outcomes for elderly patients with AML. Lancet Oncol. 2012;13(11):1065-6.
65. •• Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012;13(11):1096-104. This study showed good ORR and tolerability in elderly patients with AML
66. Kantarjian H, Garcia-Manero G, O'Brien S, et al. Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. J Clin Oncol. 2010;28(2):285-91.
67. Ravandi F, Faderl S, Cortes JE, et al. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. ASCO Meet Abstr. 2011;29(15-suppl):6587.
68. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129-39.
69. Feldman EJ, Lancet JE, Kolitz JE, et al. First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Oncol. 2011;29(8):979- 85.
70. Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX- 351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36(10):1283-9.
71. Cortes JE, Feldman EJ, Goldberg SL, et al. CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report. ASH Annu Meet Abstr. 2011;118(21):254.
72. • Lancet JE, Cortes JE, Kovacsovics T, et al. CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors. ASH Annu Meet Abstr. 2012;120(21):3626. This study showed good ORR in patients with secondary AML
73. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838-41.
74. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-60.
75. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442-52. (Pubitemid 41356159)
76. Burnett AK, Russell NH, Hills RK, et al. Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia. J Clin Oncol. 2012;30(32):3924-31.
77. Castaigne S, Pautas C, Terre C, et al. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA). ASH Annu Meet Abstr. 2011;118(21):6.
78. Hills RK, Petersdorf S, Estey EH, et al. The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. Blood. 2013;122(21): 356.
79. Sekeres MA, Lancet JE, Wood BL, et al. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119- 28.
80. Kung SutherlandMS,Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455-63.